capecitabine

Capecitabine (Capecitibine) is a fluoropyrimidine carbamate belonging to the class of antineoplastic agents called antimetabolites. As a prodrug, capecitabine is selectively activated by tumor cells to its cytotoxic moiety, 5-fluorouracil (5-FU); subsequently, 5-FU is metabolized to two active metabolites, 5-fluoro-2-deoxyuridine monophosphate (FdUMP) and 5-fluorouridine triphosphate (FUTP) by both tumor cells and normal cells. FdUMP inhibits DNA synthesis and cell division by reducing normal thymidine production, while FUTP inhibits RNA and protein synthesis by competing with uridine triphosphate for incorporation into the RNA strand.

Capecitabine-2',3'-cyclic Carbonate is a antiproliferative agent.

Capecitabine-d11 is a deuterated compound of Capecitabine. Capecitabine has a CAS number of 154361-50-9. Capecitabine is a fluoropyrimidine carbamate belonging to the class of antineoplastic agents called antimetabolites. As a prodrug, capecitabine is selectively activated by tumor cells to its cytotoxic moiety, 5-fluorouracil (5-FU); subsequently, 5-FU is metabolized to two active metabolites, 5-fluoro-2-deoxyuridine monophosphate (FdUMP) and 5-fluorouridine triphosphate (FUTP) by both tumor cells and normal cells. FdUMP inhibits DNA synthesis and cell division by reducing normal thymidine production, while FUTP inhibits RNA and protein synthesis by competing with uridine triphosphate for incorporation into the RNA strand.

Terflavoxate is a novel, orally active, semisynthetic statin microtubule inhibitor commonly used in combination with capecitabine. Terflavoxate is used in cancer research.

Uridine triacetate (RG 2133 triacetate) (Tri-O-acetyl uridine), an orally active prodrug of uridine, is efficiently absorbed in the gut and swiftly deacetylated in the circulation to release free uridine. It is utilized in the research of 5-fluorouracil (5-FU) and capecitabine toxicity, particularly targeting early-onset cardiac or central nervous system (CNS) complications.

2'',3''-Di-O-acetyl-5''-deoxy-5-fuluro-D-cytidine is a derivative of capecitabine.

5'-Deoxy-5-fluoro-N-[(pentyloxy)carbonyl]cytidine 2',3'-diacetate is an intermediate in the synthesis of capecitabine.

STAT3-IN-36 (compound 11g) is a tritarget inhibitor that selectively targets LRPPRC, STAT3, and CDK1, exhibiting potent anticancer activity. This compound binds to LRPPRC, STAT3, and CDK1, demonstrating more effective anticancer effects than those of TMF or Capecitabine. Additionally, STAT3-IN-36 exhibits an IC50 value of 1.8 μM in HGC27 cells.

5'-Deoxy-5-fluorocytidine is an intermediate metabolite of the DNA synthesis inhibitor capecitabine.

Osemitamab, an IgG1 antibody, targets human claudin-18.2 and comprises a human-Mus musculus monoclonal TST001 γ1-chain disulfide-bonded to a human-Mus musculus monoclonal TST001 κ-chain dimer (ACI). It is utilized, in conjunction with Capecitabine and Oxaliplatin, for gastric gastroesophageal junction (G GEJ) cancer studies [1] [2].

5'-Deoxy-5-fluoro-N4-[(2-methylbutoxy)carbonyl]cytidine is a Nucleoside Derivative - 5'-Modified nucleoside; 5-Modified pyrimidine nucleoside, Fluoro-modified nucleoside; Drugs and Inhibitors; 5'-Deoxy nucleoside; Capecitabine impurity E.

5'-Deoxy-5-fluoro-N4-(isopentyloxycarbonyl)cytidine is a Nucleoside Derivative - 5'-Modified nucleoside; 5-Modified pyrimidine nucleoside, Fluoro-modified nucleoside; Drugs and Inhibitors; 5'-Deoxy nucleoside; Capecitabine impurity E.